Ilenia Calcaterra: Clinical Relevance of Persistent Pain in Emicizumab-Treated Haemophilia A
Ilenia Calcaterra, Consultant Physician in Internal Medicine and Assistant Professor at the University of Naples Federico II, shared a post on LinkedIn:
“Honored to have presented our work during the free paper session at the WFH 2026 World Congress in Kuala Lumpur.
In this study, we explored the multidimensional pain experience of adults with severe haemophilia
A receiving Emicizumab prophylaxis using the Multidimensional Haemophilia Pain Questionnaire (MHPQ).
Our findings highlight an important clinical message: even in the era of highly effective bleed prevention, pain remains prevalent and functionally relevant, suggesting that haemophilia-related pain is not exclusively bleeding-driven and deserves structured, multidimensional assessment in routine care.
Grateful for the opportunity to share our data, for the stimulating scientific discussion, and for the chance to contribute to ongoing research aimed at improving the lives of people with haemophilia.”
Other posts featuring Ilenia Calcaterra on Hemostasis Today.
-
Jun 21, 2026, 19:19Tribikram Panda: Ensuring Global Equity in Management of Sickle Cell Disease
-
Jun 21, 2026, 19:15Vicken Babikian Receives Mkhitar Heratsi Medal – AAHPO
-
Jun 21, 2026, 19:11Joaqim Meireles-Brandao: Once Disease is Established, All That Remains is to Mitigate the Consequences
-
Jun 21, 2026, 18:54A Comprehensive Review of Hemophilia A and B – Journal of Thrombosis and Haemostasis
-
Jun 21, 2026, 18:54Maxime Dely: Raising Awareness and Improving Diagnosis of Sickle Cell Disease in France
-
Jun 21, 2026, 18:08Roberta Gualtierotti: Point-of-Care SPR Device for Rapid Detection of Anti-PEG Antibodies
-
Jun 21, 2026, 17:59Fakhrul Abedin Jon: Exploring Types of Brain Bleeding
-
Jun 21, 2026, 17:00Jeffrey Schnur: Advanced Treatment Strategies for Deep Vein Thrombosis and Pulmonary Embolism
-
Jun 21, 2026, 16:53Matteo Foschi: When Should We Restart Anticoagulation After a Breakthrough Ischemic Stroke?